Interleukin-33: A new frontier in cancer immunotherapy
International Review of Cell and Molecular Biology · 2025
DOI: 10.1016/bs.ircmb.2025.03.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Review of Cell and Molecular Biology, 2025. Verfasst von Amrita Kaur und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Microbiology, I…. Hauptthemen laut MEDLINE: Neoplasms, Interleukin-33, Immunotherapy. Die Arbeit nennt 316 Literaturangaben. Gefördert von: Fraser Institute, Canadian Cancer Society, National Health and Medical Research Council.
Abstract (Originalsprache)
Interleukin (IL)-33 is a member of the IL-1 cytokine family that is involved in critical physiological functions. IL-33 is constitutively expressed in the nucleus of many cell types and participates in gene regulation. However, during inflammation, IL-33 is released by cells to promote an immune response and favor tissue repair. Often referred to as an 'alarmin' due to its involvement in the early stages of inflammation, IL-33 binds to its receptor ST2 and directly modulates the activity of various immune and non-immune cell subsets. The role of the IL-33/ST2 axis has been extensively studied in reference to various inflammatory diseases and allergic responses. In cancer, this axis plays a dual role, driving pro-tumorigenic and anti-tumorigenic responses depending on the cancer type, disease stage and tumor microenvironment composition. These observations highlight the pleiotropic role exhibited by this axis in tumors. Efforts are currently being made to better understand its underlying mechanisms with the aim to exploit its therapeutic potential, alone or in combination with other anti-cancer immunotherapies. In this review, we discuss the physiological relevance of IL-33 in the context of inflammation, tumor development and progression, its impact on the tumor microenvironment, and its future application in cancer immunotherapy. Advanced understanding of the knowledge gaps and nuances pertaining to the IL-33/ST2 axis will enable the formulation of better treatments to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Microbiology, Immunology & Infectious Diseases, Cumming School of Medicine, Universit…
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
- Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Cumming School of M…
- The University of Queensland Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Förderung
- Fraser Institute
- Canadian Cancer Society
- National Health and Medical Research Council
- Alberta Cancer Foundation
- Cancer Council NSW
- Institute for Cancer Research, Keimyung University
- University of Queensland
- University of Calgary
Zitieren
APA
Kaur, A., Bittorf, K., Chanda, A., Kinzel, M., Seo, H., Yu, H., Huang, Q., Belz, G. T., Bose, P., & Jacquelot, N. (2025). Interleukin-33: A new frontier in cancer immunotherapy. International Review of Cell and Molecular Biology. https://doi.org/10.1016/bs.ircmb.2025.03.002
Vancouver
Kaur A, Bittorf K, Chanda A, Kinzel M, Seo H, Yu H, et al. Interleukin-33: A new frontier in cancer immunotherapy. International Review of Cell and Molecular Biology. 2025. doi:10.1016/bs.ircmb.2025.03.002
BibTeX
@article{Kaur2025,
author = {Kaur, Amrita and Bittorf, Kaelie and Chanda, Ayan and Kinzel, Megan and Seo, Hobin and Yu, Huiyang and Huang, Qiutong and Belz, Gabrielle T and Bose, Pinaki and Jacquelot, Nicolas},
title = {Interleukin-33: A new frontier in cancer immunotherapy},
journal = {International Review of Cell and Molecular Biology},
year = {2025},
doi = {10.1016/bs.ircmb.2025.03.002}
}
EUVIMED